Sudeep Pharma Ltd
Q1 FY27, unaudited
- Revenue
- ₹158.27 Cr
- Profit after tax
- ₹40.59 Cr
As filed with the exchange, consolidated basis.
Statement of profit and loss
Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.
| ₹ crore | Q1 FY27 | vs a year ago | FY26 |
|---|---|---|---|
| Revenue from operations | 158.27 | — | 642.26 |
| Other income | 5.45 | — | 28.59 |
| Total income | 163.72 | — | 670.84 |
| Employee benefit expense | 14.34 | — | 51.89 |
| Finance costs | 2.06 | — | 7.60 |
| Depreciation & amortisation | 4.00 | — | 14.81 |
| Total expenses | 109.42 | — | 442.77 |
| Profit before tax | 54.29 | — | 228.07 |
| Tax expense | 13.71 | — | 53.79 |
| Profit after tax | 40.59 | — | 174.28 |
| Total comprehensive income | 40.53 | — | 173.06 |
| Earnings per share, basic | ₹3.59 | ₹15.50 |
|---|---|---|
| Earnings per share, diluted | ₹3.59 | ₹15.50 |
Q1 FY27 — unaudited, from the company’s filing with NSE. Source
FY26 — from the company’s filing with NSE. Source
Why the dash
Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.
Earnings call
Q1 FY27Sudeep Pharma reported Q1 FY27 revenue growth of 27% year-on-year to Rs 158.3 crores, with EBITDA up 25% to Rs 54.9 crores and profit after tax rising to Rs 40.6 crores. Growth was driven by the pharma, food and nutrition segment which grew 31%, while specialty ingredients grew 19%, partly held back by an LPG supply shortage in April and early May. Management also discussed progress at the Sudeep Advanced Materials battery-chemicals project, the performance of the NSS European subsidiary, and a phosphoric acid price increase during the quarter.
Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary
Earlier calls: Q4 FY26 · All quarters
Filings
12 shown · 35 published by the exchange
11 Aug 2026
Transcript06 Aug 2026
Filing05 Aug 2026
05 Aug 2026
05 Aug 2026
Filing04 Aug 2026
04 Aug 2026
04 Aug 2026
Board meeting04 Aug 2026
29 Jul 2026
27 Jul 2026
25 Jul 2026
BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.
Page generated from filings held to 11 Aug 2026.